How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find out why I rate HALO stock a Buy.

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock ...

1 "We are pleased Opdivo Qvantig, which is co-formulated with our Enhanze drug delivery technology, is now FDA-approved as the first and only subcutaneously administered PD-1 inhibitor in the US ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Wells Fargo analyst Mohit Bansal has maintained their neutral stance on HALO stock, giving a Hold rating yesterday.Stay Ahead of the ...

Biotechnology pioneer Halozyme has developed ENHANZE, a drug delivery technology that can enable and optimize the subcutaneous (SC) drug delivery of coadministered therapeutics. ENHANZE is based ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), retaining the price target of $73.00.Stay ...

"Halozyme is at the forefront of drug delivery innovation, fostering a high-growth and durable business underpinned by our proprietary ENHANZE drug delivery technology. This leadership position is ...